IL205153A0 - Compositions for treating parkinson's disease - Google Patents
Compositions for treating parkinson's diseaseInfo
- Publication number
- IL205153A0 IL205153A0 IL205153A IL20515310A IL205153A0 IL 205153 A0 IL205153 A0 IL 205153A0 IL 205153 A IL205153 A IL 205153A IL 20515310 A IL20515310 A IL 20515310A IL 205153 A0 IL205153 A0 IL 205153A0
- Authority
- IL
- Israel
- Prior art keywords
- disease
- compositions
- treating parkinson
- parkinson
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0721394.5A GB0721394D0 (en) | 2007-10-31 | 2007-10-31 | Compositions for trating parkinson's disease |
PCT/GB2008/003698 WO2009056851A1 (en) | 2007-10-31 | 2008-10-31 | Compositions for treating parkinson's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
IL205153A0 true IL205153A0 (en) | 2010-11-30 |
IL205153A IL205153A (en) | 2014-11-30 |
Family
ID=38834618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL205153A IL205153A (en) | 2007-10-31 | 2010-04-15 | Dry powder compostions comprising apomorphine and magnesium stearate for treating parkinson's disease |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100288276A1 (en) |
EP (1) | EP2214649A1 (en) |
JP (1) | JP2011500869A (en) |
KR (1) | KR20100091970A (en) |
CN (1) | CN101932307A (en) |
AU (1) | AU2008320569B2 (en) |
BR (1) | BRPI0818799A2 (en) |
CA (1) | CA2703063A1 (en) |
GB (1) | GB0721394D0 (en) |
IL (1) | IL205153A (en) |
MX (1) | MX2010004614A (en) |
NZ (1) | NZ584622A (en) |
RU (1) | RU2484823C2 (en) |
SG (1) | SG185965A1 (en) |
WO (1) | WO2009056851A1 (en) |
ZA (1) | ZA201002751B (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
DE60318938T2 (en) | 2002-03-20 | 2009-01-22 | Mannkind Corp., Valencia | INHALER |
EP1786784B1 (en) | 2004-08-20 | 2010-10-27 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
CA2578175C (en) | 2004-08-23 | 2014-10-14 | Mannkind Corporation | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
US7803404B2 (en) | 2005-09-14 | 2010-09-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
BRPI0707991B8 (en) | 2006-02-22 | 2021-05-25 | Mannkind Corp | methods of preparing a dry powder medicine with an improved pharmaceutical property, said dry powder and using an effective amount of the dry powder |
EP2570147B1 (en) | 2008-06-13 | 2017-10-18 | MannKind Corporation | A dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
TWI614024B (en) | 2008-08-11 | 2018-02-11 | 曼凱公司 | Use of ultrarapid acting insulin |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
PL2405963T3 (en) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Apparatus, system and method for measuring resistance of an inhaler |
KR20180079458A (en) | 2009-06-12 | 2018-07-10 | 맨카인드 코포레이션 | Diketopiperazine microparticles with defined specific surface areas |
EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
RU2531455C2 (en) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Systems and methods for dry powder drugs delivery |
TW201304822A (en) * | 2010-11-15 | 2013-02-01 | Vectura Ltd | Compositions and uses |
CN105667994B (en) | 2011-04-01 | 2018-04-06 | 曼金德公司 | Blister package for pharmaceutical kit |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
AU2012328885B2 (en) | 2011-10-24 | 2017-08-31 | Mannkind Corporation | Methods and compositions for treating pain |
SG10201703243QA (en) * | 2012-02-28 | 2017-06-29 | Iceutica Holdings Inc | Inhalable pharmaceutical compositions |
CN108057154B (en) | 2012-07-12 | 2021-04-16 | 曼金德公司 | Dry powder drug delivery system and method |
CA2888979A1 (en) * | 2012-10-22 | 2014-05-01 | Civitas Therapeutics, Inc. | Reducing inter-patient variability of levodopa plasma concentrations |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
CA2906817C (en) | 2013-03-15 | 2022-01-18 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
GB201305825D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
WO2014205030A1 (en) * | 2013-06-19 | 2014-12-24 | Map Pharmaceuticals, Inc. | Pulmonary administration of rotigotine |
WO2014205031A1 (en) * | 2013-06-19 | 2014-12-24 | Map Pharmaceuticals, Inc. | Sustained-release formulation of rotigotine |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
JP2016530930A (en) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | Ventilation device and method |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
MA43042A (en) | 2015-09-28 | 2018-08-08 | Ever Neuro Pharma Gmbh | AQUEOUS COMPOSITION OF APOMORPHINE FOR SUBCUTANEOUS ADMINISTRATION |
EP3826620A4 (en) * | 2018-07-12 | 2023-03-08 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising dopamine agonists |
GB201912686D0 (en) * | 2019-09-04 | 2019-10-16 | Reown Pharma Inc | Pharmaceutical composition |
WO2023242355A1 (en) | 2022-06-15 | 2023-12-21 | Ever Neuro Pharma Gmbh | Apomorphine prodrugs and uses thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4742054A (en) * | 1982-11-23 | 1988-05-03 | Naftchi Nosrat E | Treatment of mammals suffering from damage to the central nervous system |
US5292520A (en) * | 1990-09-13 | 1994-03-08 | Akzo N.V. | Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer |
ATE290864T1 (en) * | 1993-03-26 | 2005-04-15 | Franciscus Wilhelmus He Merkus | PHARMACEUTICAL COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF DIHYDROERGOTAMIN |
US6395744B1 (en) * | 1994-04-22 | 2002-05-28 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
US20020165122A1 (en) * | 1994-04-22 | 2002-11-07 | Heaton Jeremy P. W. | Method and compositions for the treatment or amelioration of female sexual dysfunction |
US6566368B2 (en) * | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
DE69514794T2 (en) * | 1994-04-22 | 2000-07-27 | Pentech Pharmaceuticals Inc | SUBLINGUAL DOSAGE FORMS CONTAINING APOMORPHIN FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION |
US5744476A (en) * | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
US6413496B1 (en) * | 1996-12-04 | 2002-07-02 | Biogland Ireland (R&D) Limited | Pharmaceutical compositions and devices for their administration |
US6193954B1 (en) * | 1997-03-21 | 2001-02-27 | Abbott Laboratories | Formulations for pulmonary delivery of dopamine agonists |
EP1035833B1 (en) * | 1997-12-02 | 2005-08-31 | Archimedes Development Limited | Compositions for nasal administration |
US20020002175A1 (en) * | 2000-09-19 | 2002-01-03 | Charanjit Behl | Nasal delivery of apomorphine in combination with glycol derivatives |
US6436950B1 (en) * | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
US5994363A (en) * | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
US6858199B1 (en) * | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
BR0005797A (en) * | 2000-03-20 | 2001-10-16 | Abbott Lab | Methods for the treatment of sexual dysfunction with apomorphine at specified plasma concentration levels |
GB0007193D0 (en) * | 2000-03-25 | 2000-05-17 | Univ Manchester | Treatment of movrmrnt disorders |
CZ20023637A3 (en) * | 2000-04-07 | 2003-02-12 | Tap Pharmaceutical Products, Inc. | Apomorphine derivatives and methods of their use |
US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
SE0002934D0 (en) * | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
SE0102036D0 (en) * | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6514482B1 (en) * | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6528521B2 (en) * | 2000-11-15 | 2003-03-04 | Tap Pharmaceutical Products, Inc. | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
US20020086876A1 (en) * | 2000-11-15 | 2002-07-04 | Ruff Dustin D. | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
CA2434736A1 (en) * | 2001-01-16 | 2002-07-25 | Purdue Research Foundation | Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
CA2446904A1 (en) * | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US20040028613A1 (en) * | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
ITMI20012174A1 (en) * | 2001-10-18 | 2003-04-18 | Univ Parma | POWDER FOR NASAL DRUG ADMINISTRATION |
US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
BRPI0409380A (en) * | 2003-04-14 | 2006-04-18 | Vectura Ltd | pharmaceutical compositions |
CA2522158C (en) * | 2003-04-14 | 2018-03-20 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
US20050090518A1 (en) * | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
-
2007
- 2007-10-31 GB GBGB0721394.5A patent/GB0721394D0/en not_active Ceased
-
2008
- 2008-10-31 WO PCT/GB2008/003698 patent/WO2009056851A1/en active Application Filing
- 2008-10-31 KR KR1020107010375A patent/KR20100091970A/en not_active Application Discontinuation
- 2008-10-31 RU RU2010121827/15A patent/RU2484823C2/en not_active IP Right Cessation
- 2008-10-31 EP EP08846120A patent/EP2214649A1/en not_active Withdrawn
- 2008-10-31 CA CA2703063A patent/CA2703063A1/en not_active Abandoned
- 2008-10-31 NZ NZ584622A patent/NZ584622A/en not_active IP Right Cessation
- 2008-10-31 BR BRPI0818799 patent/BRPI0818799A2/en not_active IP Right Cessation
- 2008-10-31 SG SG2012082087A patent/SG185965A1/en unknown
- 2008-10-31 AU AU2008320569A patent/AU2008320569B2/en not_active Ceased
- 2008-10-31 JP JP2010531580A patent/JP2011500869A/en active Pending
- 2008-10-31 MX MX2010004614A patent/MX2010004614A/en not_active Application Discontinuation
- 2008-10-31 CN CN2008801230145A patent/CN101932307A/en active Pending
- 2008-10-31 US US12/740,323 patent/US20100288276A1/en not_active Abandoned
-
2010
- 2010-04-15 IL IL205153A patent/IL205153A/en not_active IP Right Cessation
- 2010-04-20 ZA ZA2010/02751A patent/ZA201002751B/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2010121827A (en) | 2011-12-10 |
KR20100091970A (en) | 2010-08-19 |
GB0721394D0 (en) | 2007-12-12 |
CN101932307A (en) | 2010-12-29 |
ZA201002751B (en) | 2011-06-29 |
RU2484823C2 (en) | 2013-06-20 |
JP2011500869A (en) | 2011-01-06 |
AU2008320569A1 (en) | 2009-05-07 |
MX2010004614A (en) | 2010-05-20 |
SG185965A1 (en) | 2012-12-28 |
EP2214649A1 (en) | 2010-08-11 |
AU2008320569B2 (en) | 2014-01-30 |
CA2703063A1 (en) | 2009-05-07 |
WO2009056851A1 (en) | 2009-05-07 |
BRPI0818799A2 (en) | 2015-04-22 |
IL205153A (en) | 2014-11-30 |
NZ584622A (en) | 2012-06-29 |
US20100288276A1 (en) | 2010-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201002751B (en) | Compositions for treating parkinson's disease | |
IL213259A0 (en) | Composition for the use to treat alzheimer's disease | |
ZA201008484B (en) | Rasagiline for parkinson's disease modification | |
IL209896A0 (en) | Compounds for treating symptoms associated with parkinson's disease | |
ZA201100034B (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
PL2197883T3 (en) | Catecholamine derivative useful for the treatment of parkinson's disease | |
PL2209458T3 (en) | Skin treatment compositions | |
IL213120A0 (en) | Method for treating parkinson' s disease | |
TWI367274B (en) | Composition for fabric treatment | |
HK1154797A1 (en) | Composition for treating disease | |
ZA201002213B (en) | "6-pyrimidinyl-pyrimid-4-one derivative" | |
EP2473176A4 (en) | Neuroprotective ganglioside compositions for use in treating or diagnosing huntington's disease | |
IL217149A0 (en) | Compositions and methods for treating parkinson's disease | |
EP2174956A4 (en) | Compositions for anti-fibrinolitic treatment | |
EP2151451A4 (en) | Composition for preventing or treating lung disease | |
EP2043662A4 (en) | Methods and compositions for treating disease | |
EP2214488A4 (en) | Compositions and methods for treating parkinson's disease and related disorders | |
EP2517698A4 (en) | Agent for treating parkinson's disease | |
EP2305629A4 (en) | Therapeutic agent for alzheimer's disease | |
EP1863510A4 (en) | Methods for treating parkinson's disease | |
EP2496080A4 (en) | Methods for treating parkinson's disease | |
IL200192A0 (en) | Composition useful for the treatment of type 2 diabetes | |
IL209804A0 (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
GB0717956D0 (en) | 20's | |
GB0707113D0 (en) | "Soote"- Sock boot |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
MM9K | Patent not in force due to non-payment of renewal fees |